

Galectin 3 (LGALS3)

Table of Content

[Purpose](#)
[Description & Definitions](#)
[Criteria](#)
[Coding](#)
[Document History](#)
[References](#)
[Special Notes](#)
[Keywords](#)

[Effective Date](#) 12/2012
[Next Review Date](#) 6/15/2024
[Coverage Policy](#) Medical 304
[Version](#) 3

All requests for authorization for the services described by this medical policy will be reviewed per Early and Periodic Screening, Diagnostic and Treatment (EPSDT) guidelines. These services may be authorized under individual consideration for Medicaid members under the age of 21-years if the services are judged to be medically necessary to correct or ameliorate the member's condition. Department of Medical Assistance Services (DMAS), Supplement B - EPSDT (Early and Periodic Screening, Diagnosis and Treatment) Manual.*.

Purpose:

This policy addresses Galectin 3 (LGALS3).

Description & Definitions:

Galectin 3 (LGALS3) is a protein that is involved with cell growth, cell death, cell division cycle, cell adhesions and other cell functions. Mutations are associated with heart disease, stroke, cancer, fibrosis and inflammation.

Criteria:

Galectin 3 (LGALS3) is considered **not medically necessary** for any indication.

Coding:

Medically necessary with criteria:

Coding	Description
	None

Considered Not Medically Necessary:

Coding	Description
82777	Galectin-3

U.S. Food and Drug Administration (FDA) - approved only products only.

Document History:

Revised Dates:

- 2020: January
- 2016: January, April
- 2015: January, February, October
- 2014: July, December
- 2013: January, February, March, July, August, September

Reviewed Dates:

- 2023: June
- 2022: June
- 2021: August
- 2020: August
- 2019: May
- 2018: May
- 2016: June, July

Effective Date:

- December 2012

References:

Including but not limited to: Specialty Association Guidelines; Government Regulations; Winifred S. Hayes, Inc; UpToDate; Literature Review; Specialty Advisors; National Coverage Determination (NCD); Local Coverage Determination (LCD).

(2023). Galectin-3 In Vitro Diagnostic Assay. US Food and Drug Administration. (6.12.2023). Retrieved 6.13.2023. <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpdc/classification.cfm?ID=659>

(2023). Galectin-3 In Vitro Diagnostic Assay (BG Medicine Inc.) For The Management Of Patients With Chronic Heart Failure. Hayes, a symplar company. ARCHIVED (11.24.2016). Retrieved 6.13.2023. <https://evidence.hayesinc.com/report/htb.galectin2719>

(2023). MCG, Informed Care Strategies. (2023). Retrieved 6.13.2023. <https://careweb.careguidelines.com/ed26/index.html>

(2023). Centers for Medicare and Medicaid Services. CMS.gov. Retrieved 6.13.2023. <https://www.cms.gov/medicare-coverage-database/search-results.aspx?keyword=&areaid=all&docType=6,3,5,1,F,P&hcpcsOption=code&hcpcsStartCode=82777&hcpcsEndCode=82777&sortBy=title>

(2023). Procedure Fee Files & CPT Codes. Virginia's Medicaid Program. Department of Medical Assistance Services. An Agency of the Commonwealth of Virginia. Retrieved 6.13.2023. <https://www.dmas.virginia.gov/for-providers/rates-and-rate-setting/procedure-fee-files-cpt-codes/#searchCPT>

(2023). Avalon Optima Health Laboratory Testing Policies. (2023). Retrieved 6.13.2023. <https://www.avalonhcs.com/policies-optimahealth/>

(2023). Aguilar, D., Sun, C., Hoogeveen, R., Nambi, V., Selvin, E., Matsushita, K., Saeed, A., McEvoy, J., Shah, A., Solomon, S., Bowewinkle, E., Ballantyne, CI, American Heart Association. Levels and Change in Galectin-3 and Association with Cardiovascular Events: The ARIC Study.

(6.23.2020). Retrieved 6.13.2023. <https://www.ahajournals.org/doi/10.1161/JAHA.119.015405>

(2023). Thomas, L., & Pasquini, L. A. (2018). Galectin-3-Mediated Glial Crosstalk Drives Oligodendrocyte Differentiation and (Re)myelination. *Frontiers in Cellular Neuroscience*. (9.12.2018). PubMed. National Library of Medicine. Retrieved 6.13.2023. <https://pubmed.ncbi.nlm.nih.gov/30258354/>

Special Notes: *

This medical policy express Sentara Health Plan's determination of medically necessity of services, and they are based upon a review of currently available clinical information. These policies are used when no specific guidelines for coverage are provided by the Department of Medical Assistance Services of Virginia (DMAS). Medical Policies may be superseded by state Medicaid Plan guidelines. Medical policies are not a substitute for clinical judgment or for any prior authorization requirements of the health plan. These policies are not an explanation of benefits.

Medical policies can be highly technical and complex and are provided here for informational purposes. These medical policies are intended for use by health care professionals. The medical policies do not constitute medical advice or medical care. Treating health care professionals are solely responsible for diagnosis, treatment and medical advice. Sentara Health Plan members should discuss the information in the medical policies with their treating health care professionals. Medical technology is constantly evolving and these medical policies are subject to change without notice, although Sentara Health Plan will notify providers as required in advance of changes that could have a negative impact on benefits.

The Early and Periodic Screening, Diagnostic and Treatment (EPSDT) covers services, products, or procedures for children, if those items are determined to be medically necessary to "correct or ameliorate" (make better) a defect, physical or mental illness, or condition (health problem) identified through routine medical screening or examination, regardless of whether coverage for the same service or support is an optional or limited service under the state plan. Children enrolled in the FAMIS Program are not eligible for all EPSDT treatment services. All requests for authorization for the services described by this medical policy will be reviewed per EPSDT guidelines. These services may be authorized under individual consideration for Medicaid members under the age of 21-years if the services are judged to be medically necessary to correct or ameliorate the member's condition. *Department of Medical Assistance Services (DMAS), Supplement B - EPSDT (Early and Periodic Screening, Diagnosis and Treatment) Manual.*

Keywords:

SHP Galectin 3, LGALS3, SHP Medical 304, IgE-Binding Protein, MAC-2, Lectin L-29, L-34 CBP-30, Gal-3, Advanced Glycation End-Product Receptor 3, Lectin, Galactoside-Binding, Soluble, 3, Carbohydrate-Binding Protein 35, CBP 35, Galactose-Specific Lectin 3, Laminin-Binding Protein, 35 KDa Lectin, Galactoside-Binding Protein, GALBP, heart disease, stroke, cancer, fibrosis, inflammation, cell growth, cell death, cell division cycle, cell adhesions, L31; GAL3; MAC2; GALIG; LGALS2